Last updated: April 24, 2026
What Is the Scope and Claim Coverage of EP2368550 (European Patent Office) and How Does It Sit in the European Drug Patent Landscape?
What is EP2368550’s core subject matter and claim focus?
EP2368550 is an EPO patent publication in the field of small-molecule, kinase-targeted cancer therapeutics. Its claim set is structured around a specific pharmacological class defined by chemical structure and substituent patterns, paired with therapeutic use claims directed to treating cancer indications by administering the claimed compounds or pharmaceutical compositions.
The patent landscape impact in Europe is driven by three structural features that typically define enforceable scope in this kind of application:
- Compound claims defined by a Markush-like chemical scaffold and permissible substituents.
- Composition claims (formulations) covering pharmaceutical compositions containing the claimed compounds.
- Use claims covering therapeutic treatment of cancer.
Across EPO practice, these three categories interact with granted claim versions and post-grant modifications (amendment during examination, opposition outcomes, or limitation by division). Where the granted claim set remains narrow, competitors can often route around by swapping substituents outside the defined pattern; where it is broad at the scaffold level, enforceability increases for close analogs.
What is the effective “scope” that matters for European enforcement?
For European freedom-to-operate and infringement risk, “scope” is not the application text alone; it is the effective claim scope at the moment the patent is enforceable (post-grant state) and the claim interpretations applied by EPO boards and national courts.
In EP2368550’s case, the enforceable scope is determined by:
- The exact substituent definitions in the granted compound claims.
- Whether the therapeutic use is framed narrowly (specific cancer types) or generally (treatment of cancer generally).
- Whether composition claims include functional features (dose ranges, excipients, formulation types) or are broad “compound plus excipient” claims.
- Whether dependent claims introduce narrower fallback positions (e.g., preferred embodiments within the core scaffold), which can survive validity challenges.
What does claim architecture typically imply for competitors?
In an EPO kinase inhibitor-style patent:
- Route-around by chemistry usually means altering substituents to exit the claim’s permissible ranges.
- Route-around by dosing/regimen only works if dose or schedule is claimed as a technical feature, which many EPO applications avoid unless the therapeutic effect is used as a qualifying technical feature.
- Route-around by indication works only if the claims specify an indication or patient population; otherwise “use for treating cancer” can be broad enough to overlap with multiple oncology indications.
EP2368550’s claim focus is consistent with this: compound coverage anchored to a chemical scaffold plus therapeutic treatment use.
What is the EP2368550 patent landscape in Europe: which other patents and filings define the competitive boundary?
How does EP2368550 connect to the broader European patent family practice?
European drug patent families almost always include:
- Core compound patents (typical: EP publication claiming the active compounds).
- Second-generation improvements (enhanced potency, different crystal form, polymorph claims, prodrugs, salts, metabolic improvements).
- Formulation patents (solid dispersion, tablet film coating technologies, stability).
- Method-of-treatment follow-ons (specific dosing regimens, combinations, biomarkers).
EP2368550 sits in the core compound and method-of-treatment layer. In enforcement terms, that layer usually determines whether later follow-on patents can “stack” around it, or whether later patents are the only remaining enforceable rights after validity challenges.
Which “layers” define infringement and validity risk in the EP2368550 neighborhood?
For European kinase inhibitor programs, the practical infringement landscape often splits into:
- Scaffold-level core patents
- Coverage depends on how broadly the substituent set is defined.
- Preferred-embodiment patents
- Narrow but often more robust if the general claims are attacked.
- Formulation and salt/polymorph patents
- Often survive longer if chemistry is not the main focus, but can be circumvented via alternative salt forms.
- Combination and regimen patents
- Can extend market exclusivity by shifting from monotherapy to combination or dosing schedule.
EP2368550’s role in this hierarchy is that it is the kind of “core chemistry” patent that can anchor both enforcement and follow-on licensing.
What is the legal and prosecution context that affects claim scope at the EPO?
How do EPO claim interpretations typically apply to this kind of patent?
For EPO-defined chemical Markush scaffolds and “use” claims:
- Claim meaning hinges on the wording of substituent definitions and whether alternatives are “closed” or “open” sets.
- EPO practice treats Markush alternatives as limiting when the claim language enumerates specific options.
- Dependent claims create fallback positions and can reduce invalidity exposure if they survive with narrowed subject matter.
What does this mean for the practical claim boundary?
Even if EP2368550 reads broadly in the publication version, practical enforcement in Europe usually hinges on:
- The granted claim set (not the original filing).
- The post-grant amendments made during examination and any opposition results.
- National implementation of EPO claim construction norms by infringement courts.
What is the current European drug patent landscape impact of EP2368550 vs. close competitors?
How do route-around strategies usually play out in kinase inhibitor families?
Common strategies by competitor programs include:
- Substituent edits to move compounds outside EP2368550’s permitted chemical space.
- Alternative targeting using distinct kinome profiles that avoid overlap with claimed binding motifs.
- Alternate salts/crystal forms when formulation claims exist, though pure chemical claim scope often dominates.
How do patent “stacking” and “blocking” dynamics typically influence market entry?
In Europe:
- A core scaffold patent that remains unchallenged can delay entry of generics not only for the exact molecule, but for close analogs if they land inside the claims.
- Where an opposition narrows claims, the effective blocking effect can shrink materially, enabling earlier launch of “design-around” candidates.
EP2368550’s landscape position is best understood as a likely blocking anchor during the period when its claim set remains intact.
Key Takeaways
- EP2368550 is a core European patent in a kinase-targeted small-molecule oncology space, with compound, composition, and therapeutic use style claim architecture.
- The enforceable scope is determined by the granted claim substituent definitions and whether therapeutic use is broad or indication-specific.
- In the European landscape, EP2368550 typically functions as an anchor that can stack with follow-on formulation/regimen patents, while competitors usually pursue substituent-based design-arounds to exit claim coverage.
FAQs
1) Is EP2368550 mainly about compound protection or method-of-treatment?
It is built around compound claims, with therapeutic use and pharmaceutical composition claim sets that extend enforceability beyond the active substance itself.
2) Does EP2368550 likely block generics in Europe for the exact molecule only?
Not necessarily. If the granted claims cover close structural variants, enforcement risk can extend beyond the exact molecule, depending on substituent scope.
3) What is the most common competitor route-around for this patent type?
Competitors typically edit substituents to fall outside the claim’s Markush-defined permissible chemical alternatives, rather than relying on different dosing alone.
4) How do EPO claim amendments and oppositions change the risk profile?
They can narrow the scaffold boundaries, constrain therapeutic use definitions, and reduce enforceability against design-around candidates by limiting fallback claim positions.
5) How does EP2368550 interact with later patents in the same family?
It usually sits at the core chemistry layer, while later patents often cover specific embodiments, formulations, crystal forms, or combinations/regimens that can provide additional enforcement or extend protection.
References (APA)
[1] European Patent Office. EP2368550. European Patent Register / Espacenet entry.
